JP2003528819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528819A5 JP2003528819A5 JP2001539402A JP2001539402A JP2003528819A5 JP 2003528819 A5 JP2003528819 A5 JP 2003528819A5 JP 2001539402 A JP2001539402 A JP 2001539402A JP 2001539402 A JP2001539402 A JP 2001539402A JP 2003528819 A5 JP2003528819 A5 JP 2003528819A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- substituted alkyl
- cycloalkyl
- cycloalkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 description 108
- 239000001257 hydrogen Substances 0.000 description 106
- 229910052739 hydrogen Inorganic materials 0.000 description 106
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 80
- 125000003342 alkenyl group Chemical group 0.000 description 54
- 239000000203 mixture Substances 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 42
- 125000000753 cycloalkyl group Chemical group 0.000 description 42
- 125000000392 cycloalkenyl group Chemical group 0.000 description 40
- 125000003118 aryl group Chemical group 0.000 description 26
- 125000000623 heterocyclic group Chemical group 0.000 description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 18
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 16
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 16
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 16
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 16
- 239000002623 mu opiate receptor antagonist Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 description 12
- 230000002093 peripheral effect Effects 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 10
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 8
- 150000001204 N-oxides Chemical class 0.000 description 8
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 8
- 125000002947 alkylene group Chemical class 0.000 description 8
- 229960004126 codeine Drugs 0.000 description 8
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 8
- 229960000920 dihydrocodeine Drugs 0.000 description 8
- 229960002428 fentanyl Drugs 0.000 description 8
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 8
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 8
- 229960000240 hydrocodone Drugs 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 8
- 229960005181 morphine Drugs 0.000 description 8
- 229960002085 oxycodone Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 229960004380 tramadol Drugs 0.000 description 8
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 8
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 8
- 239000008896 Opium Chemical class 0.000 description 6
- 150000003797 alkaloid derivatives Chemical class 0.000 description 6
- 229960004193 dextropropoxyphene Drugs 0.000 description 6
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 6
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 6
- 229960001027 opium Drugs 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 4
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 4
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 4
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 4
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 229960001391 alfentanil Drugs 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 4
- 229960001736 buprenorphine Drugs 0.000 description 4
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 4
- 229960001113 butorphanol Drugs 0.000 description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 4
- 229960003461 dezocine Drugs 0.000 description 4
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 4
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 4
- 229960001410 hydromorphone Drugs 0.000 description 4
- 229960003406 levorphanol Drugs 0.000 description 4
- 229960001797 methadone Drugs 0.000 description 4
- -1 morphinan compound Chemical class 0.000 description 4
- 229960000805 nalbuphine Drugs 0.000 description 4
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 4
- 229960005118 oxymorphone Drugs 0.000 description 4
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 4
- 229960005301 pentazocine Drugs 0.000 description 4
- 229960000482 pethidine Drugs 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- ZBAFFZBKCMWUHM-UHFFFAOYSA-N propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 description 4
- 229950003779 propiram Drugs 0.000 description 4
- 0 CC(C(CC*)C1CCCCC1)=O Chemical compound CC(C(CC*)C1CCCCC1)=O 0.000 description 3
- PCSQOABIHJXZMR-MGQKVWQSSA-O (4r,4as,7ar,12bs)-4a,9-dihydroxy-3-methyl-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CC[N+](C)(CC=C)[C@@H]3CC5=CC=C4O PCSQOABIHJXZMR-MGQKVWQSSA-O 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- JVLBPIPGETUEET-GAAHOAFPSA-O methylnaltrexone Chemical compound C[N+]1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)CC1CC1 JVLBPIPGETUEET-GAAHOAFPSA-O 0.000 description 2
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45080699A | 1999-11-29 | 1999-11-29 | |
| US09/450,806 | 1999-11-29 | ||
| PCT/US2000/042315 WO2001037785A2 (en) | 1999-11-29 | 2000-11-29 | Novel methods and compositions involving opioids and antagonists thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528819A JP2003528819A (ja) | 2003-09-30 |
| JP2003528819A5 true JP2003528819A5 (enExample) | 2008-01-24 |
Family
ID=23789563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001539402A Pending JP2003528819A (ja) | 1999-11-29 | 2000-11-29 | オピオイドおよびそのアンタゴニストに関する新規方法および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1244447B1 (enExample) |
| JP (1) | JP2003528819A (enExample) |
| AU (1) | AU784541B2 (enExample) |
| CA (1) | CA2392362A1 (enExample) |
| CY (1) | CY1106359T1 (enExample) |
| DE (1) | DE60032940T2 (enExample) |
| DK (1) | DK1244447T3 (enExample) |
| ES (1) | ES2278647T3 (enExample) |
| IL (2) | IL149600A0 (enExample) |
| MX (1) | MXPA02005335A (enExample) |
| NZ (1) | NZ518562A (enExample) |
| PT (1) | PT1244447E (enExample) |
| WO (1) | WO2001037785A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
| ES2412409T3 (es) | 1997-12-22 | 2013-07-11 | Euro-Celtique S.A. | Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo |
| SI1299104T1 (sl) | 2000-02-08 | 2009-10-31 | Euro Celtique Sa | Oralne formulacije opioidnih agonistov, varne pred zlorabo |
| US20030065002A1 (en) | 2001-05-11 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
| EP1404323B1 (en) * | 2001-06-05 | 2009-10-28 | The University of Chicago | Use of methylnaltrexone to treat immune suppression |
| AU2002316738B2 (en) | 2001-07-18 | 2009-01-08 | Euro-Celtique S.A. | Pharmaceutical combinations of oxycodone and naloxone |
| US7914818B2 (en) | 2001-08-06 | 2011-03-29 | Purdue Pharma L.P. | Opioid agonist formulations with releasable and sequestered antagonist |
| WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
| ES2320748T5 (es) | 2002-04-05 | 2017-02-20 | Euro-Celtique S.A. | Matriz para la liberación sostenida, invariable e independiente de compuestos activos |
| EP2422773A3 (en) | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
| BRPI0409133B8 (pt) | 2003-04-08 | 2021-05-25 | Progenics Pharm Inc | preparações farmacêuticas estavéis compreendendo metilnaltrexona |
| MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
| US6992090B2 (en) * | 2003-06-16 | 2006-01-31 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
| US7700626B2 (en) * | 2004-06-04 | 2010-04-20 | Adolor Corporation | Compositions containing opioid antagonists |
| JPWO2006064780A1 (ja) * | 2004-12-14 | 2008-06-12 | 塩野義製薬株式会社 | 便秘治療剤 |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| US20060211733A1 (en) * | 2005-03-04 | 2006-09-21 | Adolor Corporation | Methods of preventing and treating opioid bowel dysfunction |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| BRPI0608818A2 (pt) | 2005-03-07 | 2010-01-26 | Univ Chicago | uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| WO2006126529A1 (ja) * | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| EP1762569A1 (en) * | 2005-09-12 | 2007-03-14 | Alcasynn Pharmaceuticals Gmbh | Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics |
| JP5176188B2 (ja) | 2006-04-21 | 2013-04-03 | ディーエスエム アイピー アセッツ ビー．ブイ． | オピオイド受容体拮抗薬の使用 |
| ES2636657T3 (es) | 2006-06-19 | 2017-10-06 | Alpharma Pharmaceuticals Llc | Composición farmacéutica |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| EP2134718A2 (en) | 2007-03-29 | 2009-12-23 | Progenics Pharmaceuticals, Inc. | Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof |
| PT2139890E (pt) | 2007-03-29 | 2014-09-03 | Wyeth Llc | Antagonistas do receptor opióide periférico e respectivas utilizações |
| CA2682125C (en) | 2007-03-29 | 2015-06-16 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
| CA2694497C (en) | 2007-08-09 | 2016-07-12 | Rensselaer Polytechnic Institute | Quaternary opioid carboxamides |
| JP5905198B2 (ja) * | 2007-10-01 | 2016-04-20 | ザ ユニヴァーシティー オヴ シカゴ | 薬剤誘発性吐き気のオピオイド拮抗薬による治療 |
| CN103275004A (zh) * | 2007-11-30 | 2013-09-04 | 普渡制药公司 | 苯并吗啡烷化合物 |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| CA2713568C (en) | 2008-02-06 | 2016-09-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| UY32487A (es) | 2009-03-10 | 2010-06-30 | Euro Celtique Sa | Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona |
| SMT201900357T1 (it) | 2009-12-04 | 2019-07-11 | Alkermes Pharma Ireland Ltd | Derivati di morfinano per trattamento di abuso di sostanze stupefacenti |
| CA2793725C (en) | 2010-03-22 | 2018-05-01 | Rensselaer Polytechnic Institute | Carboxamide bioisosteres of opiates |
| SI2608670T1 (sl) | 2010-08-23 | 2019-04-30 | Alkermes Pharma Ireland Limited | Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil |
| LT2725908T (lt) | 2011-06-29 | 2017-09-11 | Alkermes, Inc. | Periferinio poveikio opioidų junginiai |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| WO2014172482A1 (en) * | 2013-04-17 | 2014-10-23 | Robert Alfred Volkmann | Compounds for treatment of pain |
| WO2014172478A1 (en) | 2013-04-17 | 2014-10-23 | VOLKMANN Robert | Compounds for treatment of pain |
| UA116567C2 (uk) | 2013-07-23 | 2018-04-10 | Євро-Селтік С.А. | Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації |
| KR102201609B1 (ko) | 2019-04-19 | 2021-01-12 | 연성정밀화학(주) | 날데메딘의 제조방법 |
| WO2022101444A1 (en) | 2020-11-12 | 2022-05-19 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US4769372A (en) * | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| PH24752A (en) * | 1987-04-16 | 1990-10-01 | Lilly Co Eli | Piperidine opioid antagonists |
| US5250542A (en) * | 1991-03-29 | 1993-10-05 | Eli Lilly And Company | Peripherally selective piperidine carboxylate opioid antagonists |
-
2000
- 2000-11-29 NZ NZ518562A patent/NZ518562A/en unknown
- 2000-11-29 JP JP2001539402A patent/JP2003528819A/ja active Pending
- 2000-11-29 WO PCT/US2000/042315 patent/WO2001037785A2/en not_active Ceased
- 2000-11-29 AU AU39706/01A patent/AU784541B2/en not_active Ceased
- 2000-11-29 IL IL14960000A patent/IL149600A0/xx unknown
- 2000-11-29 CA CA002392362A patent/CA2392362A1/en not_active Abandoned
- 2000-11-29 DE DE60032940T patent/DE60032940T2/de not_active Expired - Lifetime
- 2000-11-29 DK DK00992256T patent/DK1244447T3/da active
- 2000-11-29 MX MXPA02005335A patent/MXPA02005335A/es active IP Right Grant
- 2000-11-29 ES ES00992256T patent/ES2278647T3/es not_active Expired - Lifetime
- 2000-11-29 EP EP00992256A patent/EP1244447B1/en not_active Expired - Lifetime
- 2000-11-29 PT PT00992256T patent/PT1244447E/pt unknown
-
2002
- 2002-05-12 IL IL149600A patent/IL149600A/en not_active IP Right Cessation
-
2007
- 2007-03-07 CY CY20071100318T patent/CY1106359T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003528819A5 (enExample) | ||
| JP2005530798A5 (enExample) | ||
| US20200345718A1 (en) | Morphinan Derivatives for the Treatment of Drug Overdose | |
| US6451806B2 (en) | Methods and compositions involving opioids and antagonists thereof | |
| RU2009125597A (ru) | Пролекарства и способы их получения и применения | |
| RU2005113996A (ru) | Способы лечения боли введением антагониста фактора роста нервов и опиоидного анальгетика, и содержащие их композиции | |
| JP2010511717A5 (enExample) | ||
| SI1436012T1 (en) | Polymer conjugates of opioid antagonists | |
| JP2003517476A5 (enExample) | ||
| CA2547334A1 (en) | Methods and compositions for deterring abuse of opioid containing dosage forms | |
| RU2004106619A (ru) | Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист | |
| JP2011515495A5 (enExample) | ||
| WO2001037785A9 (en) | Novel methods and compositions involving opioids and antagonists thereof | |
| JP2011519930A5 (enExample) | ||
| RU2007139827A (ru) | Фармацевтические композиции для лечения боли | |
| JP2008534564A5 (enExample) | ||
| CO5590940A2 (es) | Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo | |
| KR102720795B1 (ko) | 중수소화 덱스트로메토르판의 합성 방법 | |
| AU2016244249A1 (en) | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | |
| WO2009121018A4 (en) | Opioid-nornicotine codrugs for pain management | |
| JP2005500373A5 (enExample) | ||
| JP2017526719A5 (enExample) | ||
| JP2007503473A5 (enExample) | ||
| JP2018534319A5 (enExample) | ||
| JP2005533046A5 (enExample) |